Cullinan Therapeutics, Inc. Net Income Loss

Quick Answer

Cullinan Therapeutics, Inc. reported Net Income Loss of -$219.88 million for the year ending 2025.

  • Cullinan Therapeutics, Inc. showed a decrease of -31.4% in Net Income Loss from 2024 to 2025.
  • This data is from Cullinan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Cullinan Therapeutics, Inc.'s Net Income Loss has declined by 324.5%.
  • Historical annual values: Fiscal year 2025: -$219.88 million | Fiscal year 2024: -$167.38 million | Fiscal year 2023: -$153.16 million | Fiscal year 2022: $111.21 million | Fiscal year 2021: -$65.57 million | Fiscal year 2020: -$51.80 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: